tetano
Editor, Senior Moderator
Infect Dis Ther
. 2022 Nov 28.
doi: 10.1007/s40121-022-00730-9. Online ahead of print.
Clinical Utility of Circulating Pentraxin 3 as a Prognostic Biomarker in Coronavirus Disease 2019: A Systematic Review and Meta-analysis
Yani Ke[SUP] #[/SUP][SUP] 1 [/SUP], Kaihan Wu[SUP] #[/SUP][SUP] 2 [/SUP], Chenglu Shen[SUP] 2 [/SUP], Yuqing Zhu[SUP] 2 [/SUP], Chuchu Xu[SUP] 2 [/SUP], Qiushuang Li[SUP] 3 [/SUP], Jie Hu[SUP] 4 [/SUP], Shan Liu[SUP] 5 [/SUP]
Affiliations
Abstract
Introduction: Pentraxin 3 (PTX3) is involved in inflammation regulation and has a certain association with infectious diseases. However, its specific correlation with infectious diseases remains controversial. This study aimed to analyze the association between them and explore the possible role of PTX3 in the prognosis of coronavirus disease 2019 (COVID-19).
Methods: Five databases (PubMed, Cochrane Library, Embase, Clinicaltrials.gov, and gray literature) were searched. Outcomes were expressed as a standardized mean difference (SMD) and 95% confidence intervals (CI). The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of included articles. Stata 12 and Meta-DiSc were applied to analyze the pooled data. Receiver operating characteristic (ROC) curves were conducted to determine the prognostic value of PTX3 for mortality.
Results: Six articles met the inclusion criteria. Circulating PTX3 levels had a nonsignificant difference between intensive care unit (ICU) and non-ICU patients with COVID-19 [SMD 1.37 (-0.08, 2.81); I[SUP]2[/SUP] = 93.9%, P < 0.01], while the PTX3 levels in nonsurvival COVID-19 patients was significantly lower than those in survival patients [SMD -1.41 (-1.92, -0.91); I[SUP]2[/SUP] = 66.4%, P = 0.051]. Circulating PTX3 had good mortality prediction ability (area under ROC curve, AUC = 0.829) in COVID-19. Funnel plots and Egger's tests showed low probabilities of publication bias. Through sensitivity analysis, the results of this study were robust.
Conclusion: This study found that PTX3 was differentially expressed between survival and nonsurvival patients with COVID-19, while there was no significant difference between ICU and non-ICU patients. Meanwhile, circulating PTX3 may be a good biomarker for monitoring the prognosis of COVID-19, which may provide new ideas and directions for clinical and scientific research.
Keywords: COVID-19; Coronavirus disease; Meta-analysis; PTX3; Pentraxin 3.
. 2022 Nov 28.
doi: 10.1007/s40121-022-00730-9. Online ahead of print.
Clinical Utility of Circulating Pentraxin 3 as a Prognostic Biomarker in Coronavirus Disease 2019: A Systematic Review and Meta-analysis
Yani Ke[SUP] #[/SUP][SUP] 1 [/SUP], Kaihan Wu[SUP] #[/SUP][SUP] 2 [/SUP], Chenglu Shen[SUP] 2 [/SUP], Yuqing Zhu[SUP] 2 [/SUP], Chuchu Xu[SUP] 2 [/SUP], Qiushuang Li[SUP] 3 [/SUP], Jie Hu[SUP] 4 [/SUP], Shan Liu[SUP] 5 [/SUP]
Affiliations
- PMID: 36443545
- DOI: 10.1007/s40121-022-00730-9
Abstract
Introduction: Pentraxin 3 (PTX3) is involved in inflammation regulation and has a certain association with infectious diseases. However, its specific correlation with infectious diseases remains controversial. This study aimed to analyze the association between them and explore the possible role of PTX3 in the prognosis of coronavirus disease 2019 (COVID-19).
Methods: Five databases (PubMed, Cochrane Library, Embase, Clinicaltrials.gov, and gray literature) were searched. Outcomes were expressed as a standardized mean difference (SMD) and 95% confidence intervals (CI). The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of included articles. Stata 12 and Meta-DiSc were applied to analyze the pooled data. Receiver operating characteristic (ROC) curves were conducted to determine the prognostic value of PTX3 for mortality.
Results: Six articles met the inclusion criteria. Circulating PTX3 levels had a nonsignificant difference between intensive care unit (ICU) and non-ICU patients with COVID-19 [SMD 1.37 (-0.08, 2.81); I[SUP]2[/SUP] = 93.9%, P < 0.01], while the PTX3 levels in nonsurvival COVID-19 patients was significantly lower than those in survival patients [SMD -1.41 (-1.92, -0.91); I[SUP]2[/SUP] = 66.4%, P = 0.051]. Circulating PTX3 had good mortality prediction ability (area under ROC curve, AUC = 0.829) in COVID-19. Funnel plots and Egger's tests showed low probabilities of publication bias. Through sensitivity analysis, the results of this study were robust.
Conclusion: This study found that PTX3 was differentially expressed between survival and nonsurvival patients with COVID-19, while there was no significant difference between ICU and non-ICU patients. Meanwhile, circulating PTX3 may be a good biomarker for monitoring the prognosis of COVID-19, which may provide new ideas and directions for clinical and scientific research.
Keywords: COVID-19; Coronavirus disease; Meta-analysis; PTX3; Pentraxin 3.